Serum insulin‐like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis

Although experimental studies have demonstrated an important role of insulin‐like growth factor I (IGF‐I) in hepatocarcinogenesis, the clinical data about IGF‐I in patients with hepatocellular carcinoma (HCC) are scarce and controversial. To the authors' knowledge, this is the first prospective study investigating the longitudinal correlation between modifications in serum IGF‐I levels and the development of HCC in a cohort of patients with hepatitis C virus (HCV)‐related cirrhosis.

[1]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[2]  G. Ramadori,et al.  The IGF axis and hepatocarcinogenesis , 2001, Molecular pathology : MP.

[3]  C. Mantzoros,et al.  Insulin‐like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men , 2000, International journal of cancer.

[4]  M. Zeniya,et al.  Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C , 2000, Cancer.

[5]  A. Renehan,et al.  Response: More About: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF- Binding Protein-3 , 1999 .

[6]  E. Giovannucci.  Insulin-Like Growth Factor-I and Binding Protein-3 and Risk of Cancer , 1999, Hormone Research in Paediatrics.

[7]  M. Shaarawy,et al.  Insulin-like growth factor binding protein-3: a novel biomarker for the assessment of the synthetic capacity of hepatocytes in liver cirrhosis. , 1998, The Journal of clinical endocrinology and metabolism.

[8]  David J Hunter,et al.  Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.

[9]  Meir J. Stampfer,et al.  Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study , 1998 .

[10]  L. Seeff,et al.  Natural history of hepatitis C , 1997, Hepatology.

[11]  M. Rechler.  Editorial: Growth Inhibition by Insulin-Like Growth Factor (IGF) Binding Protein-3-What's IGF Got To Do with It? , 1997, Endocrinology.

[12]  M. Rubini,et al.  The IGF-I receptor in cell growth, transformation and apoptosis. , 1997, Biochimica et biophysica acta.

[13]  P. Cohen,et al.  Insulin-like Growth Factor (IGF)-binding Protein-3 Induces Apoptosis and Mediates the Effects of Transforming Growth Factor-β1 on Programmed Cell Death through a p53- and IGF-independent Mechanism* , 1997, The Journal of Biological Chemistry.

[14]  T. Sohda,et al.  Immunohistochemical evidence of insulin‐like growth factor II in human small hepatocellular carcinoma with hepatitis C virus infection: Relationship to fatty change in carcinoma cells , 1997, Journal of gastroenterology and hepatology.

[15]  J. G. Park,et al.  Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene product. , 1996, Cancer research.

[16]  I. de Sio,et al.  Activation of fetal promoters of insulinlike growth factors II gene in hepatitis C virus–related chronic hepatitis, cirrhosis, and hepatocellular carcinoma , 1996, Hepatology.

[17]  H. Herbst,et al.  Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. , 1996, The American journal of pathology.

[18]  R. Baserga,et al.  Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. , 1995, Cancer research.

[19]  K. Michaelsen,et al.  Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. , 1995, The Journal of clinical endocrinology and metabolism.

[20]  Mariana,et al.  The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. , 1995, Cancer research.

[21]  P. Bedossa,et al.  Transforming growth factor—beta 1 (TGF‐β1) and TGF‐β1 receptors in normal, cirrhotic, and neoplastic human livers , 1995, Hepatology.

[22]  R. Baserga.  The insulin-like growth factor I receptor: a key to tumor growth? , 1995, Cancer research.

[23]  N. Skakkebaek,et al.  Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. , 1994, The Journal of clinical endocrinology and metabolism.

[24]  Kenzo Kobayashi,et al.  Prospective study of α‐fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma , 1994 .

[25]  M. Pinzani,et al.  Circulating growth hormone and insulin-like growth factor-I in nonalcoholic liver cirrhosis with or without superimposed hepatocarcinoma: evidence of an altered circadian rhythm. , 1993, The American journal of gastroenterology.

[26]  M. Colombo,et al.  Hepatocellular carcinoma in Italian patients with cirrhosis. , 1991, The New England journal of medicine.

[27]  J. Prieto,et al.  Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. , 1991, The New England journal of medicine.

[28]  C. Bréchot,et al.  Expression of insulin‐like growth factor II, α‐fetoprotein and hepatitis B virus transcripts in human primary liver cancer , 1991 .

[29]  Chou Ck,et al.  Radioimmunoassay of serum IGF-I and IGF-II in patients with chronic liver diseases and hepatocellular carcinoma with or without hypoglycemia. , 1988 .

[30]  K. Okuda.  Early recognition of hepatocellular carcinoma , 1986, Hepatology.

[31]  E. Feller,et al.  Alpha-fetoprotein (AFP) in benign liver disease. Evidence that normal liver regeneration does not induce AFP synthesis. , 1978, Gastroenterology.

[32]  T. Waldmann,et al.  alpha-fetoprotein in noneoplastic hepatic disorders. , 1975, JAMA.

[33]  T. Waldmann,et al.  α-Fetoprotein in Nonneoplastic Hepatic Disorders , 1975 .

[34]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.

[35]  H. Lee,et al.  Transforming growth factor‐β1 as a useful serologic marker of small hepatocellular carcinoma , 2002 .

[36]  Stampfer,et al.  Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. , 1999, Journal of the National Cancer Institute.

[37]  M. Rechler.  Growth inhibition by insulin-like growth factor (IGF) binding protein-3--what's IGF got to do with it? , 1997, Endocrinology.

[38]  F Vignon,et al.  [Growth factors and cancer]. , 1994, Journal de gynecologie, obstetrique et biologie de la reproduction.

[39]  N. Hopkins.  Insulin-like growth factor-I and its binding proteins. , 1992 .

[40]  B. le Bail,et al.  Localization of insulin-like growth factor-II and hepatitis B virus mRNAs and proteins in human hepatocellular carcinomas. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[41]  C. Bréchot,et al.  Expression of insulin-like growth factor II, alpha-fetoprotein and hepatitis B virus transcripts in human primary liver cancer. , 1991, Hepatology.

[42]  R. Purcell,et al.  Etiology, pathology, and treatment of hepatocellular carcinoma in North America , 1991 .

[43]  B. Chiang,et al.  Radioimmunoassay of serum IGF-I and IGF-II in patients with chronic liver diseases and hepatocellular carcinoma with or without hypoglycemia. , 1988, The Journal of laboratory and clinical medicine.